Skip to main content

News74

Sep 22
Love0

Aranscia Announces Molecular Laboratory Integration Initiative with Northside Hospital to Advance Precision Oncology

By News

Aranscia Announces Molecular Laboratory Integration Initiative with Northside Hospital to Advance Precision Oncology

Initiative integrates Aranscia’s 2bPrecise and Spesana platforms with leading molecular laboratories to streamline genomic testing across Northside’s cancer care network

ATLANTA, GA — September 22, 2026 — Aranscia today announced a new initiative with Northside Hospital Cancer Institute designed to advance precision medicine and improve the integration of molecular diagnostic testing throughout its health system. Through the collaboration with Northside, Aranscia and its network of 12 leading molecular laboratories are creating a more connected molecular diagnostic ecosystem designed to make genomic testing easier to order, results easier to access, and clinically relevant information more actionable for physicians and care teams.

Historically, disparate laboratories have operated through different ordering processes, reporting formats, and technology platforms. This fragmentation can create challenges for clinicians and care teams seeking to efficiently order testing, track results, and incorporate molecular findings into treatment decisions.

Through this integration, Aranscia’s platform of software solutions, including 2bPrecise and Spesana, will enhance Northside Hospital Cancer Institute’s existing clinical, operational and analytical workflows with unified molecular diagnostic reports and discrete genomic data directly within Northside’s Oracle Health system. This functionality will help clinicians more efficiently incorporate diagnostic information into coordinated, patient-centered care. Northside clinicians will also benefit from the translation of complex genetic data into actionable insights that can guide treatment planning, help identify therapy opportunities, and support long-term patient care.

“This initiative represents an important step in our continued efforts to bring precision medicine into the everyday clinical workflow,” said Amy Boren, Director of Oncology Services at Northside Hospital. “By connecting our clinicians with a broader molecular laboratory ecosystem, we can help make genomic testing more accessible, more coordinated, and more actionable. Most importantly, this work is about ensuring that patients and their care teams can derive the greatest possible value from the increasingly important role of molecular diagnostics in cancer care.”

Beyond the immediate benefits, this integration also provides Northside with a foundation for continued innovation in precision oncology and genomic medicine. As the volume and complexity of molecular testing continues to grow, the ability to efficiently manage, organize, and utilize genomic information will become increasingly important to delivering high-quality care.

“Northside Hospital Cancer Institute has built a reputation for delivering exceptional cancer care to those directly within its communities,” said Carla Balch, Executive Director, Software & Products at Aranscia. “We are honored to support their continued leadership in precision medicine and their commitment to improving access and outcomes for all patients, directly within clinical EHR workflows.”

About Northside Hospital

Northside Hospital is Georgia’s leading healthcare system, serving patients at five acute-care hospitals in Atlanta, Canton, Cumming, Duluth and Lawrenceville and nearly 500 outpatient locations across the state. Northside is nationally recognized for world-class patient care, innovation and clinical excellence. The system leads the U.S. in newborn deliveries and stands among the state’s top providers of cancer care, cardiovascular, sports medicine, neuroscience, robotics and surgical services. Learn more at northside.com.

About Aranscia

Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more, visit www.aranscia.com.

About 2bPrecise

2bPrecise, an Aranscia company, is a suite of diagnostic and precision medicine technologies that enable transformative solutions at the point of care. 2bPrecise efficiently routes genetic and genomic data from molecular labs and clinical data sets, synthesizing them into a single clinical-genomic workflow. Precision medicine insights are incorporated into a clinician’s EHR workflow for immediate and timely use, with specialty application for oncology, pharmacogenomics, hereditary screening, and more. With discrete test results consolidated into an invaluable data set, provider organizations are equipped to drive efficient workflows for a range of genomic workflows including population analytics, clinical intervention programs, and research. For more information on 2bPrecise, please visit www.2bPrecise.com.

About Spesana

Spesana, an Aranscia company, has developed a universal healthcare platform to increase the velocity of patient access to the right care through improving clinical, financial, and operational workflows. Founded in 2019 by an experienced team of electronic medical record pioneers, Spesana’s framework for purpose driven healthcare interoperability incorporates a provider-centric approach to building solutions for challenges such as patient navigation, referral management, prior authorization, lab routing, and multi-site clinical collaboration. For more information on Spesana, please visit www.spesana.com.

Media Contact

Karina Stabile
Aria Marketing for Aranscia
(516) 317-5835
kstabile@ariamarketing.com

Katherine Watson
Northside Hospital
(404) 303-3405
katherine.watson@northside.com

SOURCE: Aranscia

Jun 30
Love0

InterVenn Biosciences And Aranscia Expand Commercialization Partnership For GlycoKnow™ Ovarian Cancer Diagnostic Test

By News

Aranscia’s Technology Platform to Accelerate InterVenn’s Research and Commercialization Initiatives

SOUTH SAN FRANCISCO, Calif. and HOUSTON, June 30, 2026 /PRNewswire/ — InterVenn Biosciences, a life sciences company unlocking the value of glycoproteomics for the development of transformational healthcare solutions, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced an expansion of their commercialization partnership to broaden access to InterVenn’s flagship GlycoKnow™ Ovarian cancer diagnostic test for clinicians and researchers.

Aranscia and InterVenn previously announced a multi-year partnership providing InterVenn with access to Aranscia’s platform of clinical workflow software solutions, including Spesana and 2bPrecise, to drive commercialization of GlycoKnow Ovarian. The expanded scope broadens access to InterVenn’s diagnostic solutions across Aranscia’s expansive network of health systems, multi-site women’s health and oncology groups, and individual physicians. Additional Aranscia platform solutions will also help to improve the fidelity and efficiency of supporting insights for InterVenn’s research studies in concert with a growing base of clinical partners, including the delivery of longitudinal insights at the point of care.

“We’re pleased to reach these milestones with the Aranscia team and expand our commercialization efforts for GlycoKnow Ovarian,” said Andrew Quong, CEO of InterVenn. “The Aranscia team is an ideal partner that understands and addresses tactical gaps in existing clinical workflows. In addition, Aranscia’s technology platform helps to eliminate the friction in physician adoption, which is critical for executing clinical studies that support the value and utility of novel diagnostics in positively impacting a patient’s care journey.”

GlycoKnow Ovarian is a proprietary blood-based liquid biopsy test that helps clinicians distinguish ovarian cancer from benign pelvic masses. By helping to distinguish the 80% of pelvic masses that are benign through a non-invasive blood test, GlycoKnow Ovariancan improve risk stratification and support surgical decision making, helping clinicians determine the most appropriate care as quickly as possible, potentially reducing unnecessary procedures and associated complications. GlycoKnow Ovarian is available from InterVenn as a laboratory-developed test. For more information on GlycoKnow Ovarian, or to inquire about participating in InterVenn’s early access program for this ovarian cancer test, please visit https://intervenn.com/products/.

“The pace at which we have advanced our technical and commercial partnership with InterVenn from vision to production underscores Aranscia’s proven commitment to speed-to-value in precision medicine,” said Bryon Cipriani, CEO of Aranscia. “This is only the beginning of what we believe will be a strong long-term relationship that will help bring the benefit of glycoproteomics into practice for providers, researchers, and most importantly, the patients they serve.”

About GlycoKnow™ Ovarian

GlycoKnow™ Ovarian is a proprietary blood-based test measuring serum glycopeptides, combined with an algorithm to assess the likelihood of malignancy. It is a laboratory-developed test (LDT) intended for use in women 18 years of age or older with a documented pelvic/adnexal mass for which surgical intervention is being considered. The test provides an assessment of the likelihood of malignancy to assist in clinical decision making. It is intended for use as an adjunct to, not a replacement for, standard clinical and radiological evaluation. It is not intended for use as a screening test for the general population or as a standalone diagnostic. GlycoKnow Ovarian is currently available through select clinical partners and early access programs. InterVenn is currently working to expand commercial access and coverage.

InterVenn’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) to perform high complexity clinical laboratory testing and complies with College of American Pathologists (CAP) Proficiency Testing requirements. The GlycoKnow Ovarian test was developed and its performance characteristics were determined by InterVenn. The GlycoKnow Ovarian test has not been cleared or approved by the U.S. Food and Drug Administration.

About InterVenn Biosciences

InterVenn Biosciences is advancing precision medicine through glycoproteomics—an innovative approach that reveals critical biological signals traditional genomics and proteomics cannot see. By leveraging artificial intelligence and deep glycoproteomic analysis, InterVenn maps the glycoprotein control points that orchestrate disease progression, enabling earlier detection, more precise clinical insights, and improved patient outcomes. InterVenn’s mission is to unlock the full potential of the glycoproteome to transform diagnostics and personalize patient care across women’s health, oncology, and other complex diseases. To learn more, visit intervenn.com.

About Aranscia

Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more, visit https://www.aranscia.com/.

Press Contact

Karina Stabile
Aria Marketing
516-317-5835

SOURCE Aranscia

Jan 07
Love0

InterVenn Biosciences Partners With Aranscia To Accelerate Commercialization Of GlycoKnow™ Non-Invasive Ovarian Cancer Diagnostic Test

By News

SOUTH SAN FRANCISCO & HOUSTON – January 7, 2026  InterVenn Biosciences, a precision diagnostics company advancing liquid biopsy with glycoproteomics, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership where Aranscia technical and laboratory resources will help to facilitate clinical workflows and expand the availability of InterVenn’s flagship GlycoKnowTM Ovarian cancer diagnostic test.

Under this multi-year partnership, the Aranscia suite of software solutions, including Spesana and 2bPrecise, will provide InterVenn with software-based, electronic-medical-record (EMR)-agnostic clinical workflow utilities, facilitating InterVenn’s delivery of diagnostic results and insights within a wide range of women’s health, oncology, and health system care settings. Additionally, AccessDx Laboratory, also an Aranscia company, will provide InterVenn with logistical program support resources.  Aranscia solutions currently support thousands of discrete client groups, including leading health systems, municipalities, Accountable Care Organizations, and multi-provider organizations.

“We’re pleased to be partnering with the Aranscia team in our mission to improve the care and treatment journey for all who may benefit from the insights afforded by GlycoKnow Ovarian and potential additional GlycoKnow tests in the future,” said Andrew Quong, CEO of InterVenn.  “Aranscia’s legacy of enabling end-to-end personalized diagnostic programs, as well as their demonstrated capabilities in serving the unique needs of those in oncology and women’s health, make them an ideal collaborator and partner in our mission to advance care through our innovations in glycoproteomics.”

GlycoKnow Ovarian is a proprietary blood-based liquid biopsy test that helps distinguish ovarian cancer from benign pelvic masses.  By helping to distinguish the 80% of pelvic masses that are benign through a non-invasive blood test, GlycoKnow Ovarian enables clinicians and the women they treat to receive the most appropriate care as quickly as possible, while also helping to reduce unnecessary procedures and associated complications.  GlycoKnow Ovarian is available from InterVenn as a laboratory-developed test. For more information on GlycoKnow Ovarian, or to inquire about participating in InterVenn’s early access program for this ovarian cancer test, please visit https://intervenn.com/products/.

“We’re proud to support InterVenn’s mission to accelerate the efficiency of detection and care in the battle against ovarian cancer,” said Bryon Cipriani, CEO of Aranscia. “This partnership builds upon the foundational efforts and platform assets of the Aranscia family of companies to democratize access to the power of precision care, and will benefit from our extensive experience in commercialization to help InterVenn deliver actionable intelligence at the point of care.”

###

About InterVenn Biosciences

InterVenn Biosciences decodes the human glycoproteome as a rich source of biological insight to advance personalized, predictive, and preventative care.  InterVenn has pioneered a proprietary technology platform, GlycoVision™, to tap into this layer of biology through AI and machine learning at a clinically meaningful scale.  InterVenn has become a key partner to patients, physicians, researchers, and biopharma organizations navigating the frontier of glycoproteins and their relevance in human health and disease.  InterVenn’s glycoproteomic insights help inform decisions about disease detection, treatment strategies, and research priorities.  For more information about InterVenn, visit https://intervenn.com.

About Aranscia

Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes.  The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows.  Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening.  With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives.  For more, visit https://www.aranscia.com/.

 

Press Contact

KarinaStabile
Aria Marketing
516-317-5835
kstabile@ariamarketing.com

Oct 16
Love0

DPYD Safety Update: Reducing The Risk Of Critical Or Fatal Chemotherapy Side Effects

By News

Aranscia® solutions help oncologists comply with new FDA warning label requiring  DPYD genetic testing in patients receiving select chemotherapies

HOUSTON, Oct. 16, 2025 /PRNewswire/ — Oncologists and pharmacy experts are reacting to last week’s Food and Drug Administration warning that requires genetic testing on patients receiving the common chemotherapy drug capecitabine (Xeloda®) – and are actively seeking technologies that allow them to leverage these test results within their clinical workflows. Aranscia, a leading provider of personalized, precision diagnostics and clinical workflow solutions, equips providers with discrete diagnostic, clinical decision support, and software solutions. These are designed to help identify patients who harbor DPYD variants, streamline the test-ordering workflow, and deliver actionable reports and insights at the point of care.

“A concerning number of patients have difficulty metabolizing capecitabine and fluorouracil, which are commonly used to treat a wide range of cancers,” noted Houda Hachad, PharmD and Vice President of Clinical Operations at Aranscia. The DPYD gene produces dihydropyrimidine dehydrogenase (DPD), an enzyme responsible for metabolizing these medications. DPYD gene variants may cause DPD deficiencies, leading to dangerously high or toxic accumulations of these drugs.

Between 3% and 8% of the general population carries one copy of variants associated with lower DPD metabolizing capacity.

Early in October, the FDA updated the label for Genentech’s Xeloda (capecitabine), explicitly requiring providers to assess patient genetic risk for severe toxicities from this commonly prescribed chemotherapy prior to treatment. The so-called “black box warning” on the Xeloda label now states: “Serious adverse reactions or death may occur in patients with complete DPD deficiency. Test patients for genetic variants of DPYD prior to initiating Xeloda unless immediate treatment is necessary. Avoid use of Xeloda in patients with certain homozygous or compound heterozygous DPYD variants that result in complete DPD deficiency.”

“Advocates for pre-treatment DPYD testing believe that the FDA will likewise revise labelling for fluorouracil to require testing,” adds Dr. Hachad.

“A number of diagnostic laboratories offer standalone and panel solutions for DPYD testing,” she continues, “but providers are encountering workflow barriers that impede their ability to adopt this testing as standard of care and to access results when and where they need them.” This is especially critical since testing is required before important treatment is initiated.

While some leading academic medical centers have successfully developed technological solutions in-house, she said, other health systems and community oncology centers – where 80 percent of cancer patients are treated – may lack the time, personnel, and financial resources to build a ground-up solution. The Aranscia software portfolio (which includes 2bPrecise®, Spesana, and YouScript®) can accommodate the “round trip” testing workflow from identifying patients, to ordering the appropriate test, to delivering timely reports, and surfacing vital information via alerts and notifications within the patient’s electronic medical record.

“Ensuring fast and efficient rapid access to high-quality testing, along with providing oncologists with actionable insights before treatment, is crucial,” Dr. Hachad emphasized. “Furthermore, Aranscia’s capability to integrate and unify siloed genomic results from various cancer diagnostics into clinically meaningful intelligence supports organizations as they manage diverse DPYD test results (e.g., incidental), as well as other important cancer biomarkers.”

About Aranscia

Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, has extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening. With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives. For more information, please visit www.aranscia.com.

Media Contact
Karina Stabile
516-317-5835

Jun 26
Love0

Spartanburg Regional Healthcare System (SRHS) Deploys 2bPrecise Enterprise

By News

Multi-year partnership affirms SHRS as a leader in precision care and genomics

SPARTANBURG, S.C. and HOUSTON, June 25, 2025 /PRNewswire/ — Spartanburg Regional Healthcare System (SRHS) today announced its deployment of the 2bPrecise® enterprise platform. Under this multi-year partnership, 2bPrecise-powered applications are now available across the SRHS care network, including a base of 700 physicians, six hospitals, and over 150 offices. The platform efficiently delivers, supports, and expands transformative precision care solutions directly within EHR workflows.

SRHS selected multiple 2bPrecise-powered applications to support its system-wide genomics and precision care objectives, including for specialty oncology providers. 2bPrecise Diagnostic Workflow enables the delivery and utility of discrete results from multiple specialty laboratory providers; 2bPrecise Oncology Workflow provides specialty assessment capabilities for both somatic and germline data, potential therapies, and clinical trials; and 2bPrecise Precision Timeline‘s patented longitudinal framework helps providers easily analyze an entire patient’s care history, interventions, and therapeutic processes. 2bPrecise also enables SRHS’s support of population-scale pharmacogenomics and personalized medication management programs, powered by YouScript.

“This partnership with 2bPrecise reinforces SRHS’s commitment to precision medicine and healthcare innovation leadership, making it easier than ever for providers to access, assess, and incorporate precision care solutions into their existing workflows,” said Charles Morrow, MD, Executive Vice President and Chief Operating Officer, SRHS. “SRHS is proud of initiatives that help improve care efficiency and increase the availability of innovative, personalized care for all patients we serve, and we look forward to expanding upon these efforts with 2bPrecise.”

2bPrecise Enterprise is the flagship operating system for precision medicine, enabling care organizations to efficiently route and utilize discrete diagnostic results, genomic insights, and multi-source system data. Compared with single-use applications with limited utility, siloed solutions from data-hungry aggregators, or bespoke initiatives that often require years of costly, resource-intensive development, 2bPrecise Enterprise is a vendor-agnostic, EHR-agnostic platform that provides unmatched speed-to-value for the universal adoption and continued expansion of precision medicine solutions.

“On behalf of the entire 2bPrecise team, we are excited to reach our production milestones with SHRS,” said Joe Spinelli, Chief Strategy Officer, 2bPrecise. “The modular and scalable framework of 2bPrecise Enterprise is a perfect match with SHRS’s ambition and vision to systematically unlock the true power of personalized medicine. We look forward to continuing to expand the scope of applications and impact from these programs.”

###

About Spartanburg Regional Healthcare System
Founded in 1917, Spartanburg Regional Healthcare System (SRHS) is an integrated healthcare delivery system and one of the largest providers of regional care in South Carolina. With a mission of advancing health together, SRHS’ footprint includes over six hospital campuses and 150 offices, and employs more than 10,000 associates and 700 physicians. For more, visit https://spartanburgregional.com.

About 2bPrecise
2bPrecise®, an Aranscia company, is a suite of diagnostic and precision medicine technologies that enable transformative solutions at the point of care. 2bPrecise efficiently routes genetic and genomic data from molecular labs and clinical data sets, synthesizing them into a single clinical-genomic workflow. Precision medicine insights are incorporated into a clinician’s EHR workflow for immediate and timely use, with specialty application for oncology, pharmacogenomics, hereditary screening, and more. With discrete test results consolidated into an invaluable data set, provider organizations are equipped to drive efficient workflows for a range of genomic workflows including population analytics, clinical intervention programs, and research. For more information on 2bPrecise, please visit www.2bPrecise.com.

Media Contact
Karina Stabile
Aria Marketing for 2bPrecise
(516) 317-5835
397179@email4pr.com

SOURCE 2bPrecise

May 21
Love0

Neurogen Biomarking Announces Partnership with Aranscia

By News

Aranscia Diagnostic Laboratory and Technology Solutions Support Neurogen’s Innovative Platform for the Early Detection of Mild Cognitive Impairment (MCI) and Alzheimer’s Dementia

CHICAGO and HOUSTON, May 21, 2025 /PRNewswire/ — Neurogen Biomarking, the world’s first ecosystem for memory loss with end-to-end patient support, and Aranscia, a global provider of award-winning clinical workflow and diagnostic technology solutions, today announced a partnership in which Aranscia’s technical and laboratory resources will help to deliver clinical insights and HIPAA-compliant connectivity for the Neurogen Biomarking ecosystem.

Under this partnership, AccessDx Laboratory, an Aranscia company, will provide Neurogen with technical, operational, and analytical support resources for its blood-based biomarker test that measures phosphorylated tau (p-tau) 217, a specific marker for Alzheimer’s disease pathology. AccessDx Laboratory is a CAP-accredited, CLIA-certified, NYSDOH-approved diagnostic laboratory focused on both the development and scaling of novel diagnostic programs.

In addition, 2bPrecise, another Aranscia company, will provide Neurogen with software-based, EMR-agnostic clinical workflow utilities that help to securely integrate Neurogen’s diagnostic results and programmatic insights across the Neurogen ecosystem and within a wide range of clinical care settings. 2bPrecise’s HIPAA-compliant software solutions currently support thousands of discrete client groups, including leading health systems, municipalities, ACOs, and multi-provider organizations.

“Neurogen’s driving force is to solve the issue of delayed detection and ultimately diagnosis by empowering patients in a scientifically and clinically controlled ecosystem while also guiding them every step of the way in their brain health journey,” said Dr. Rany Aburashed, CEO and Founder of Neurogen Biomarking. “Aranscia’s proven experience in supporting a wide range of complex diagnostic and clinical workflows, combined with their expertise in enabling innovative and secure end-to-end personalized diagnostic programs, makes them the ideal partner to help us both achieve our objectives and position for scale.”

Neurogen’s platform is the first patient-initiated system designed to shift the paradigm of early detection of Alzheimer’s disease (AD) through improved access to innovative blood biomarker testing and AI-enhanced digital and cognitive assessments. Board-certified neurologists will support eligible Neurogen patients every step of the way via telehealth, providing follow-up care if indicated and accelerating access to expert cognitive care – delivered in weeks rather than the months-long wait times typically seen in traditional neurology care.

“We’re proud to partner with Neurogen on its mission to accelerate early detection and interventionist care in the fight against Alzheimer’s disease, which has become all too personal for millions of Americans and their families,” said Bryon Cipriani, CEO of Aranscia. “This partnership builds upon the foundational efforts of AccessDx Laboratory and 2bPrecise in helping to democratize access to personalized and precision care for all, and in ways that proactively and positively impacts the lives of the patients we help to serve.”

Aranscia joins Neurogen’s collaborators Linus Health, which is providing the cutting-edge digital cognitive assessments for patients with memory concerns on the Neurogen Biomarking platform; Quanterix Corporation, a company fueling scientific discovery through ultrasensitive biomarker detection; and NeuroX, a venture of American TelePhysicians, to provide virtual neurology services that help guide the patient journey on its brain health care ecosystem. The platform will be widely available in mid-2025 for anyone with eligible memory and thinking concerns.

Approximately 7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2024. It is estimated that 40% of Americans age 65+ experience memory impairment, affecting around 16 million people. Only 8% of Americans living with mild cognitive impairment receive a diagnosis, leaving 92% undiagnosed. The process of developing Alzheimer’s disease is slow, with 15-20 years before the onset of Mild Cognitive Impairment (MCI). MCI precedes Alzheimer’s disease by many years.

About Neurogen Biomarking
Neurogen Biomarking is dedicated to supporting early detection of Alzheimer’s disease and Mild Cognitive Impairment. Founded by award-winning neurologist, Dr. Rany Aburashed and guided by world-renowned brain health experts, Neurogen is on a mission to empower anyone with thinking and memory concerns with the tools, education, and motivation needed to access advanced, personalized care of patients with Alzheimer’s disease – and a future with more in it. To learn more visit www.neurogenbiomarking.com or follow us on LinkedIn.

About Aranscia 
Aranscia delivers world-class diagnostic software, services, and testing innovations that help clinicians improve care outcomes. The Aranscia portfolio of companies, which includes 2bPrecise, AccessDx Laboratory, Spesana, and YouScript, have extensive practical expertise in molecular diagnostics, genomics, and digital-first clinical workflows. Aranscia enables clinical organizations to effectively utilize precision diagnostics for turnkey programs in fields such as pharmacogenomics, infectious disease management, precision oncology, and genetic screening.  With a dual focus on simplicity and scalability, Aranscia’s portfolio companies are the ideal partner for long-term, value-based precision medicine initiatives.  For more information, please visit www.aranscia.com.

Media Contacts:
Neurogen Biomarking
395551@email4pr.com
872.240.3696

Aranscia
395551@email4pr.com
516.317.5835

SOURCE Aranscia

Read the source press release here.

Mar 07
Love0

PGx Biomarker Testing: Covered Soon for All Californians

By News

Good news for CA providers and residents!

Starting July 1, 2024, Pharmacogenomic (PGx) biomarker testing will be a covered benefit for all Californians*, regardless of insurance provider. PGx testing is already a covered benefit for Medicare patients.

Read the press release below, and learn more on the American Cancer Society’s Cancer Action Network website.

Read the legislation here.

*For insured Californians meeting testing criteria mandated by California Senate Bill 496.

 

 

Governor Newsom Signs Game-Changing Legislation Aimed at Improving Health Outcomes, Quality of Life for Californians

 

CANCER ADVOCATES APPLAUD GOV. NEWSOM FOR SIGNING THE BIPARTISAN BILL TO ENSURE MORE PATIENTS CAN ACCESS BIOMARKER TESTING THAT CAN CONNECT THEM TO THE RIGHT TREATMENT AT THE RIGHT TIME

 

October 7, 2023

 

SACRAMENTO, Calif. – California Governor Gavin Newsom announced he has signed Senate Bill 496 on Saturday, ensuring that more health insurance plans, including Medi-Cal, cover comprehensive biomarker testing when supported by medical and scientific evidence. The bill, sponsored by the American Cancer Society Cancer Action Network (ACS CAN) and the University of California, received strong, bipartisan support throughout the legislative process.

“We thank the Legislature and Governor Newsom for taking this crucial step to turn the promise of precision medicine into a reality for more Californians. A longstanding leader in health equity and medical innovation, California joins twelve other states that have enacted similar legislation,” said Dr. Karen E. Knudsen, CEO of ACS CAN. “This action ensures California continues to pave the way for the fight against cancer and other chronic diseases and will improve access to the most effective treatments – including those in clinical trials – giving patients a better chance of living longer, healthier lives.”

“People of color, individuals with limited income, and rural residents are less likely to receive biomarker testing,” said Autumn J. Ogden-Smith, California Legislative Director for ACS CAN. “Improving coverage for biomarker testing across insurance types prevents patients from being forced to pay out-of-pocket, incur debt, or go without this game-changing testing, and is fundamental to reducing health disparities as precision medicine grows.”

Testing for specific biomarkers – such as gene mutations – found in blood, tissues or other biospecimens – is the key to unlocking precision medicine, including targeted therapies, that often improve survivorship and quality of life for cancer patients and others with chronic diseases.

“Biomarker testing can help health care providers render the right treatment at the right time and is increasingly important for cancer care and the treatment of diseases like arthritis and other autoimmune and rare diseases. With research happening in other areas, biomarkers may be available in the future to treat Alzheimer’s, neurological conditions, and more,” said State Senator Monique Limón (D-Santa Barbara), the author of the legislation. “This bill removes barriers to precision medicine and can potentially reduce overall health care costs by avoiding unnecessary hospitalizations and treatments.”

Punita Khanna, a breast cancer survivor, bypassed chemotherapy thanks to her biomarker testing results indicating a low risk of recurrence.

“I had to undergo radiation and hormone therapy, which produced its own side effects – such as excruciating bone and joint pain – but nothing like what I might have experienced if I had to undergo chemotherapy,” said Khanna.

Clinical trials fuel medical innovation and the development of new cancer treatments and are increasingly driven by biomarker testing, which facilitates participation by helping identify eligible patients. Nearly 60% of all cancer drugs approved in the last five years require or recommend biomarker testing before use.

“In July 2021, I was diagnosed with stage-four lung cancer after developing symptoms that I thought were from COVID. Within weeks, I could barely stand and would go unconscious and wake up in an ambulance. I went on chemotherapy, and it was doing more damage. My family and I were preparing for my imminent death,” said César Serrano. “Then, I received the biomarker testing results that led doctors to the treatment that saved my life. It was truly a miracle.”

For more information on precision medicine, cancer biomarkers, current barriers to biomarker testing and ACS CAN’s policy recommendations, visit www.fightcancer.org/biomarkers.

May 03
Love0

2bPrecise Named “Best Overall Genomics Company” in 2023 MedTech Breakthrough Awards Program

By News

 

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies

 

[Houston, TX] – May 3, 2023 – 2bPrecise, a leading provider of transformative precision medicine solutions, today announced that it is the recipient of the “Best Overall Genomics Company” award in the 7th annual MedTech Breakthrough Awards. The program, conducted by MedTech Breakthrough – an independent market intelligence organization – recognizes the top companies, technologies, and products in the global health and medical technology market.

The 2bPrecise software platform provides health systems, municipal agencies, and care organizations with a suite of solutions that democratize access to genomic insights. 2bPrecise’s solutions for pharmacogenomics, oncology, and hereditary screening help providers more easily obtain and utilize the insights from laboratory diagnostic results across the entire care ecosystem. 2bPrecise also features pedigree and candidate management solutions to help population health managers easily and proactively identify opportunities for engagement.

In 2022, 2bPrecise expanded native support for more health systems, including the two largest global EMR vendors and a growing number of care-specific platforms serving the long-term care industry. Through in-workflow presentation and advanced analytical tools, such as the precision medicine timeline, 2bPrecise ensures that clinicians can easily reference the data elements from these tests for additional analysis or support of clinical research initiatives. In addition, 2bPrecise has recently added support for diagnostic ordering and resulting for hundreds of diagnostic tests from leading laboratories focused on oncology, rare diseases, and hereditary screening.

“We are committed to building and delivering solutions that lead the market and meet the needs of clinical partners, and this pace of innovation has only increased with our continued growth. Through our ongoing platform expansion, customer growth, and strategic investments in developing innovative software-based clinical workflow tools, we continue to realize our vision to enable transformative genomics solutions at the point of care,” said 2bPrecise Founder Assaf Halevy. “This recognition from MedTech Breakthrough reflects our dedication to the ever-evolving needs of clinical professionals with tools to help maximize the benefits of precision genomics.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work, and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data, and many more. This year’s program attracted more than 4,000 nominations from over 17 countries worldwide.

“Personalized medicine is emerging as a standard of care across clinical applications. However, health systems are encountering complex logistics issues that prevent a seamless workflow of ordering, resulting, and alerting forcomplex molecular diagnostic tests. There are multiple barriers to easily and effectively delivering results and insights within the native EMR workflow,” said James Johnson, managing director of MedTech Breakthrough. “We’re thrilled to recognize 2bPrecise again as our ‘Best Overall Genomics Company’ as they continue to help close long-standing health disparity gaps and support turnkey programs that are enabling a new wave of successful, high-utility genomics programs.”

####

About 2bPrecise

The cloud-based 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs, synthesizing them into a clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) brings the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use. With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more.

About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.

Media Contact

Ashley DuBray
Senior Marketing Director
Ashley.DuBray@2bPreciseHealth.com

 

May 10
Love0

2bPrecise Named “Best Overall Genomics Company” in 2022 MedTech Breakthrough Awards Program

By News

Prestigious Annual Awards Program Recognizes Outstanding Health & Medical Technology Products and Companies

PITTSBURGH, PA, – May 5, 2022 – 2bPrecise, a leading provider of transformative precision medicine solutions, today announced that it has been selected as the winner of the “Best Overall Genomics Company” award in the sixth annual MedTech Breakthrough Awards Program.  This program is conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global health and medical technology markets.

The cloud-based 2bPrecise Precision Health™ platform delivers actionable clinical-genomic workflow directly to providers at point-of-care through their native EHR systems. 2bPrecise synthesizes results from molecular labs – including a range of pharmacogenomics, precision oncology, and heredity genetic tests – and delivers them as discrete data to augment patient records and empower true clinical decision support. This deeper and unified understanding of how the patient’s genetic makeup can be used to assist in overall care decisions can be applied across a range of care disciplines, including primary care, obstetrics and gynecology, oncology, cardiology, pediatrics, and more.

The 2bPrecise platform also includes tools to help better capture and analyze additional data points to aid in treatment decisions, such as an advanced digital pedigree tool, risk assessments, cohort analyses, and dynamic patient timeline views.  Germline test results can be utilized in 2bPrecise to enable the provider to make a highly accurate diagnosis and identify the most effective therapy.

“On behalf of the entire 2bPrecise team, I sincerely thank MedTech Breakthrough for their recognition,” said Assaf Halevy, Founder and CEO of 2bPrecise. “This award affirms our years of continuous commitment to building actionable, high-utility informatics layers for precision medicine data.  As we look ahead, our ongoing platform expansion will incorporate additional innovations that profoundly help to impact patient outcomes.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data and many more. This year’s program attracted more than 3,900 nominations from over 15 different countries throughout the world.

“As we’ve witnessed the maturation of precision medicine technologies over the past several years, it’s increasingly apparent that solving the ‘last mile’ challenges of data utility and clinical decision support are key elements to program success,” said James Johnson, managing director, MedTech Breakthrough. “2bPrecise has been singularly focused on solving the practical challenges that have long vexed healthcare organizations, making it easier to initiate their precision medicine strategies and deliver real impact to the patients they serve. Congratulations on being our choice for ‘Best Overall Genomics Company.’”

About 2bPrecise

The 2bPrecise platform consumes genetic/genomic data from molecular labs and clinical information from EHRs to create an actionable clinical-genomic ontology. The 2bPrecise Genomic EHR Mentor (GEM™) seamlessly integrates the resulting precision medicine insights into a physician’s EHR workflow for immediate and timely use.  With discrete test results consolidated into an invaluable data set, provider organizations are likewise equipped to drive efficient workflows for genomic interventions, extract population analytics, design clinical intervention programs, build cohorts for trial recruitment, enable participation in research studies and more.  For more information, visit www.2bPrecisehealth.com.

About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.

Media Contact:

Karina Stabile
Senior Account Executive
Aria Marketing for 2bPrecise
516-317-5835
kstabile@ariamarketing.com